TRANSCODE THERAPEUTICS, INC.
  • Home
    • Mission
    • Clinical Trials
  • About
    • Metastatic Disease
    • Lead Candidate
    • Science
    • Pipeline >
      • Delivery Platform
      • Other Products
    • Leadership
  • Publications
  • Investors
  • Partnering

Publications

TransCode Publications

Linked references in italics below are authored by TransCode's scientific co-founders
  • Anna Moore, N A. Savan,  Paulo V. Saavedra, Alan Halim, Vilma Yuzbasiyan-Gurkan, Ping Wang, Byunghee Yoo, Matti Kiupel, Lorenzo Sempere, Zdravka Medarova: Case Report: microRNA-10b as a Therapeutic Target in Feline Metastatic Mammary Carcinoma and its Implications for Human Clinical Trials. Frontiers in Oncology October 26, 2022 12:959630
  • Le Fur et al.,: Radiolabeling and PET–MRI micro-dosing of the experimental cancer therapeutic, MN‑anti‑miR10b, demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancer. Cancer Nanotechnology 2021;12(1):16.
  • Byunghee Yoo, Alana Ross, Pamela Pantazopoulos & Zdravka Medarova: miRNA10b-directed nanotherapy effectively targets brain metastases from breast cancer, Scientific Reports volume 11, Article number: 2844 (2021)
  •  Sheedy, P, Medarova, Z: The fundamental role of miR-10b in metastatic cancer. Am J Cancer Res 2018;8(9):1674-1688.
  • Yoo B, Greninger P, Stein GT, Egan RK, McClanaghan J, Moore A, et al. (2018) Potent and selective effect of the mir-10b inhibitor MN-anti- mir10b in human cancer cells of diverse primary disease origin. PLoS ONE 13(7): e0201046 2018.
  • Yoo B, Fuchs BC and Medarova Z: New Directions in the Study and Treatment of Metastatic Cancer. Frontiers in Oncology Volume 8, Article 258, July 2018
  • Yoo B, Kavishwar, A, Wang, P, Ross, A, Pantazopoulos,P Dudley, M, Moore, A, & Medarova, Z: Therapy targeted to the metastatic niche is effective in a model of stage IV breast cancer. Scientific Reports 21 March 2017 7:45060 | DOI: 10.1038/srep45060.
  • Yoo B, Kavishwar A, Ross A, Wang P, Tabassum DP, Polyak K, Barteneva N, Petkova V, Pantazopoulos P, Tena A, Moore A, Medarova Z: Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer. Cancer Res 2015, 75:4407-4415.​
  • Yoo B, Kavishwar A., Ghosh SK, Barteneva N, Yigit MV, Moore A. Medarova Z.: Detection of miRNA Expression in Intact Cells Using Activatable Sensor Oligonucleotides. Chemistry & Biology 21, 199–204, February 20, 2014
  • Yoo B, Ghosh SK, Kumar M, Moore A, Yigit MV, Medarova Z: Design of nanodrugs for miRNA targeting in tumor cells. J Biomed Nanotechnol 2014;10:1114-1122​
  • Yigit MV, Ghosh SK, Kumar M, Petkova V, Kavishwar A, Moore A, Medarova Z: Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis. Oncogene 2013;32:1530-1538​​

Posters

  • Oligonucleotide Therapeutics Society 2022 Poster
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.

Home

Mission
clinical trials
careers

​

About

​METASTATIC DISEASE
TTX-MC138
​SCIENCE
​PIPELINE
​DELIVERY PLATFORM
​OTHER PRODUCTS
​LEADERSHIP


Publications

​PUBLICATIONS

Partnering

partnering

Contact/Support

CONTACT
​TERMS OF USE
PRIVACY POLICY
FCOI Policy
​
© TRANSCODE THERAPEUTICS, INC. 2025.​ ALL RIGHTS RESERVED.
  • Home
    • Mission
    • Clinical Trials
  • About
    • Metastatic Disease
    • Lead Candidate
    • Science
    • Pipeline >
      • Delivery Platform
      • Other Products
    • Leadership
  • Publications
  • Investors
  • Partnering